Cellectis (CLLS) Liabilities and Shareholders Equity (2016 - 2025)
Cellectis has reported Liabilities and Shareholders Equity over the past 12 years, most recently at $324.7 million for Q4 2025.
- Quarterly results put Liabilities and Shareholders Equity at $324.7 million for Q4 2025, down 15.34% from a year ago — trailing twelve months through Dec 2025 was $1.3 billion (up 8.4% YoY), and the annual figure for FY2025 was $324.7 million, down 15.34%.
- Liabilities and Shareholders Equity for Q4 2025 was $324.7 million at Cellectis, down from $383.5 million in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for CLLS hit a ceiling of $383.5 million in Q4 2024 and a floor of $209.7 million in Q3 2023.
- Median Liabilities and Shareholders Equity over the past 5 years was $324.7 million (2025), compared with a mean of $303.3 million.
- Biggest five-year swings in Liabilities and Shareholders Equity: plummeted 31.63% in 2022 and later grew 27.97% in 2023.
- Cellectis' Liabilities and Shareholders Equity stood at $382.1 million in 2021, then tumbled by 31.63% to $261.2 million in 2022, then rose by 27.97% to $334.3 million in 2023, then rose by 14.74% to $383.5 million in 2024, then decreased by 15.34% to $324.7 million in 2025.
- The last three reported values for Liabilities and Shareholders Equity were $324.7 million (Q4 2025), $383.5 million (Q4 2024), and $334.3 million (Q4 2023) per Business Quant data.